We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
Read MoreHide Full Article
Key Takeaways
QDEL cut 2026 revenue, adjusted EBITDA and earnings guidance on weaker China and respiratory demand.
QuidelOrtho expects China challenges through 2026 as pricing changes drive faster inventory reductions.
QDEL used $143.6 million in operating cash as total debt rose to $2.89 billion, increasing leverage pressure.
QuidelOrtho Corporation (QDEL - Free Report) sharply lowered its 2026 outlook after second-quarter results as China purchasing weakened and management adopted more conservative respiratory-season assumptions. The reset reduces near-term earnings visibility and raises the importance of cash conversion.
Core businesses are still growing, but the lower revenue, EBITDA and earnings ranges show that those gains are not enough to offset the company’s largest near-term pressures. The revised outlook also makes balance-sheet improvement harder to achieve.
QDEL’s Guidance Reset Is Material
QuidelOrtho now expects 2026 revenues of $2.52-$2.60 billion, down from its prior $2.70-$2.75 billion range. The cut reflects weaker demand expectations in China and a softer respiratory environment.
Adjusted EBITDA guidance fell to $540-$560 million from $615-$630 million, while adjusted earnings expectations dropped to 65-90 cents per share from $1.80-$2.00. The scale of the reductions points to a materially weaker earnings trajectory for the remainder of the year.
China Pricing Changes Hit QDEL’s Demand Outlook
The second draft of China’s in-vitro diagnostics pricing guidelines changed the market backdrop. Management said the draft broadened product coverage, removed methodology and use-case differentiation and expanded the pilot from three provinces to six.
After quarter-end, customers reduced inventories more quickly and significantly than QuidelOrtho had anticipated. Final guidelines and implementation timing remain uncertain, and management expects China challenges to persist through the remainder of 2026.
Image Source: Zacks Investment Research
QDEL Turns More Cautious on Respiratory Demand
QuidelOrtho has shifted away from using an average respiratory season as its planning baseline. It now assumes the second-half respiratory environment will be closer to the lower end of historical seasons.
Management cited U.S. positivity rates that were significantly below year-ago levels and Southern Hemisphere data that suggested either a later or softer season. That more conservative stance reduces the earnings recovery previously expected from seasonal testing demand.
Core QDEL Businesses Provide a Partial Offset
Second-quarter Labs revenues rose 3.6% year over year, Immunohematology increased 1.4% and Point of Care advanced 16.3% on a reported basis. Excluding China, total revenues grew 6% at constant currency, showing that the broader portfolio retains pockets of resilience.
The competitive diagnostics backdrop remains active. Abbott Laboratories (ABT - Free Report) reported $3.1 billion in second-quarter 2026 Diagnostics sales, while Danaher Corporation (DHR - Free Report) reported 7% year-over-year Diagnostics revenue growth. QDEL’s core growth is encouraging, but it was not sufficient to prevent the full-year outlook reduction.
QDEL’s Cash Conversion Adds to the Consequences
Operating activities used $143.6 million of cash during the first six months of 2026 compared with cash generation a year earlier. QuidelOrtho also withdrew its free cash flow guidance because of uncertainty tied to China, respiratory demand and working-capital effects.
Total debt increased to $2.89 billion at quarter-end from $2.69 billion at the end of the first quarter. With earnings visibility reduced, improving cash conversion becomes more important to the company’s efforts to lower leverage and strengthen the balance sheet.
QDEL’s Bearish Signal Reflects the Outlook Reset
The guidance reduction leaves QuidelOrtho facing a difficult near-term setup. Core growth provides some support, but China uncertainty, respiratory volatility, cash use and elevated debt keep the risk-reward balance unfavorable.
The stock currently carries a Zacks Rank #5 (Strong Sell). QDEL has a Value Score of B, which points to relatively favorable value characteristics, but its Growth Score of F and Momentum Score of F indicate weak growth and momentum traits. Its VGM Score of D further signals an unfavorable combined profile. Because Style Scores complement the Zacks Rank, this mix reinforces a cautious view even though the value reading is stronger than the other style factors.
View the Zacks #1 Rank List
Image: Bigstock
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
Key Takeaways
QuidelOrtho Corporation (QDEL - Free Report) sharply lowered its 2026 outlook after second-quarter results as China purchasing weakened and management adopted more conservative respiratory-season assumptions. The reset reduces near-term earnings visibility and raises the importance of cash conversion.
Core businesses are still growing, but the lower revenue, EBITDA and earnings ranges show that those gains are not enough to offset the company’s largest near-term pressures. The revised outlook also makes balance-sheet improvement harder to achieve.
QDEL’s Guidance Reset Is Material
QuidelOrtho now expects 2026 revenues of $2.52-$2.60 billion, down from its prior $2.70-$2.75 billion range. The cut reflects weaker demand expectations in China and a softer respiratory environment.
Adjusted EBITDA guidance fell to $540-$560 million from $615-$630 million, while adjusted earnings expectations dropped to 65-90 cents per share from $1.80-$2.00. The scale of the reductions points to a materially weaker earnings trajectory for the remainder of the year.
China Pricing Changes Hit QDEL’s Demand Outlook
The second draft of China’s in-vitro diagnostics pricing guidelines changed the market backdrop. Management said the draft broadened product coverage, removed methodology and use-case differentiation and expanded the pilot from three provinces to six.
After quarter-end, customers reduced inventories more quickly and significantly than QuidelOrtho had anticipated. Final guidelines and implementation timing remain uncertain, and management expects China challenges to persist through the remainder of 2026.
Image Source: Zacks Investment Research
QDEL Turns More Cautious on Respiratory Demand
QuidelOrtho has shifted away from using an average respiratory season as its planning baseline. It now assumes the second-half respiratory environment will be closer to the lower end of historical seasons.
Management cited U.S. positivity rates that were significantly below year-ago levels and Southern Hemisphere data that suggested either a later or softer season. That more conservative stance reduces the earnings recovery previously expected from seasonal testing demand.
Core QDEL Businesses Provide a Partial Offset
Second-quarter Labs revenues rose 3.6% year over year, Immunohematology increased 1.4% and Point of Care advanced 16.3% on a reported basis. Excluding China, total revenues grew 6% at constant currency, showing that the broader portfolio retains pockets of resilience.
The competitive diagnostics backdrop remains active. Abbott Laboratories (ABT - Free Report) reported $3.1 billion in second-quarter 2026 Diagnostics sales, while Danaher Corporation (DHR - Free Report) reported 7% year-over-year Diagnostics revenue growth. QDEL’s core growth is encouraging, but it was not sufficient to prevent the full-year outlook reduction.
QDEL’s Cash Conversion Adds to the Consequences
Operating activities used $143.6 million of cash during the first six months of 2026 compared with cash generation a year earlier. QuidelOrtho also withdrew its free cash flow guidance because of uncertainty tied to China, respiratory demand and working-capital effects.
Total debt increased to $2.89 billion at quarter-end from $2.69 billion at the end of the first quarter. With earnings visibility reduced, improving cash conversion becomes more important to the company’s efforts to lower leverage and strengthen the balance sheet.
QDEL’s Bearish Signal Reflects the Outlook Reset
The guidance reduction leaves QuidelOrtho facing a difficult near-term setup. Core growth provides some support, but China uncertainty, respiratory volatility, cash use and elevated debt keep the risk-reward balance unfavorable.
The stock currently carries a Zacks Rank #5 (Strong Sell). QDEL has a Value Score of B, which points to relatively favorable value characteristics, but its Growth Score of F and Momentum Score of F indicate weak growth and momentum traits. Its VGM Score of D further signals an unfavorable combined profile. Because Style Scores complement the Zacks Rank, this mix reinforces a cautious view even though the value reading is stronger than the other style factors.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.